Ventrus Biosciences, Inc. (VTUS) Completes Enrollment Of Second Pivotal Phase 3 Trial Of Diltiazem Cream (VEN 307) In Patients With Anal Fissure
11/25/2013 9:23:41 AM
NEW YORK, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced that it has completed patient enrollment and randomization in the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). Ventrus anticipates that data from this Phase 3 study will be available in the first quarter of 2014, and it expects to file a New Drug Application (NDA) for VEN 307 in the second quarter of 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by